[Dyspeptic syndrome associated with antidiabetic therapy]

Area of Science:

• Gastroenterology
• Pharmacology
• Endocrinology

Background:

• Dyspeptic syndrome is a frequent adverse effect of antidiabetic medications.
• Symptoms range from mild nausea and diarrhea to more severe abdominal pain.
• These complications can impact patient adherence to treatment regimens.

Purpose of the Study:

• To review the common gastrointestinal complications associated with various antidiabetic drugs.
• To highlight the incidence and management of dyspeptic symptoms in patients using these medications.
• To inform clinicians about potential side effects and patient counseling strategies.

Main Methods:

• Literature review of adverse events reported for antidiabetic drugs.
• Analysis of common symptoms associated with metformin, acarbose, orlistat, and incretin-based therapies.
• Examination of the severity and management of dyspeptic syndromes.

Main Results:

• Metformin commonly causes nausea, vomiting, diarrhea, and abdominal pain, rarely leading to discontinuation.
• Acarbose is associated with dyspeptic syndrome, manageable with reduced sucrose intake; pneumatosis cystoides intestinalis is a rare complication.
• Orlistat frequently causes dyspeptic symptoms, especially with high-fat diets.
• Incretin-based therapies (DPP-4 inhibitors, GLP-1 RAs) rarely cause pancreatitis; GLP-1 RAs may cause transient initial dyspeptic symptoms.

Conclusions:

• Dyspeptic syndrome is a prevalent complication of antidiabetic drug therapy, varying in severity.
• Most dyspeptic symptoms are manageable and do not necessitate treatment cessation.
• Understanding these side effects is crucial for optimizing patient care and adherence to diabetes treatment.